Adenoid Cystic Carcinoma Clinical Trial
Official title:
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University Hospital, with a combination of carbon ions and photons. So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); patients are followed up for further 5 years after the start of therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70% after 5 years (primary objective criterion of this study). In order to reject the null hypothesis with a power of 80% and a significance level of 5%, 175 patients are included (including a drop-out rate of 15%). Secondary objective criteria are progression-free survival, overall survival, acute and late toxicity, and quality of life.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04973683 -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
|
Phase 1 | |
| Completed |
NCT01417143 -
Dovitinib in Adenoid Cystic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05010629 -
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04801264 -
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
|
Early Phase 1 | |
| Completed |
NCT03319641 -
PSMA-PET Imaging for Advanced ACC/SDC
|
N/A | |
| Recruiting |
NCT02942693 -
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
|
Phase 2 | |
| Completed |
NCT00581360 -
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
| Not yet recruiting |
NCT05553782 -
Drug Screening Using Novel IMD in ACC and Salivary Cancers
|
Early Phase 1 | |
| Completed |
NCT04291300 -
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT02775370 -
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
|
Phase 2 | |
| Active, not recruiting |
NCT02780310 -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
|
Phase 2 | |
| Completed |
NCT04119453 -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
|
Phase 2 | |
| Active, not recruiting |
NCT02098538 -
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
| Completed |
NCT01524692 -
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
|
Phase 2 | |
| Completed |
NCT01558661 -
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
| Recruiting |
NCT01192087 -
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04209660 -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
|
Phase 2 | |
| Recruiting |
NCT05774899 -
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
|
Phase 1/Phase 2 |